Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Knowledge of HIV/AIDS among older adults (50 years and above) in a peri-urban setting: a descriptive cross-sectional study.

Anokye R, Acheampong E, Budu-Ainooson A, Obeng EI, Tetteh E, Acheampong YS, Nettey-Marbell CE.

BMC Geriatr. 2019 Nov 11;19(1):304. doi: 10.1186/s12877-019-1335-4.

PMID:
31711421
2.

Factors Affecting Caregivers' Acceptance of the Use of Wearable Devices by Patients With Dementia: An Extension of the Unified Theory of Acceptance and Use of Technology Model.

Dai B, Larnyo E, Tetteh EA, Aboagye AK, Musah AA.

Am J Alzheimers Dis Other Demen. 2019 Nov 3:1533317519883493. doi: 10.1177/1533317519883493. [Epub ahead of print]

PMID:
31679390
3.

Reducing avoidable medication-related harm: What will it take?

Tetteh EK.

Res Social Adm Pharm. 2019 Jul;15(7):827-840. doi: 10.1016/j.sapharm.2019.04.002. Epub 2019 Apr 5.

PMID:
30981449
4.

Rubber and plantain intercropping: Effects of different planting densities on soil characteristics.

Tetteh EN, Abunyewa AA, Tuffour HO, Berchie JN, Acheampong PP, Twum-Ampofo K, Dawoe E, Logah V, Agbenyega O, Ennin SA, Nunoo I, Melenya C, Owusu Danquah E, Barnes VR, Partey ST.

PLoS One. 2019 Jan 9;14(1):e0209260. doi: 10.1371/journal.pone.0209260. eCollection 2019.

5.

Discrete-choice modelling of patient preferences for modes of drug administration.

Tetteh EK, Morris S, Titcheneker-Hooker N.

Health Econ Rev. 2017 Dec;7(1):26. doi: 10.1186/s13561-017-0162-6. Epub 2017 Jul 27.

6.

Higher serum concentrations of vimentin and DAKP1 are associated with aggressive breast tumour phenotypes in Ghanaian women.

Arko-Boham B, Lomotey JT, Tetteh EN, Tagoe EA, Aryee NA, Owusu EA, Okai I, Blay RM, Clegg-Lamptey JN.

Biomark Res. 2017 Jun 9;5:21. doi: 10.1186/s40364-017-0100-0. eCollection 2017.

7.

Estimating preferences for modes of drug administration: The case of US healthcare professionals.

Tetteh EK, Morris S, Titchener-Hooker N.

Res Social Adm Pharm. 2018 Jan;14(1):86-95. doi: 10.1016/j.sapharm.2017.02.003. Epub 2017 Feb 16.

PMID:
28279612
8.

Characterizing Class-Specific Exposure-Viral Load Suppression Response of HIV Antiretrovirals Using A Model-Based Meta-Analysis.

Xu Y, Li YF, Zhang D, Dockendorf M, Tetteh E, Rizk ML, Grobler JA, Lai MT, Gobburu J, Ankrom W.

Clin Transl Sci. 2016 Aug;9(4):192-200. doi: 10.1111/cts.12395. Epub 2016 May 12.

9.

Evaluating the administration costs of biologic drugs: development of a cost algorithm.

Tetteh EK, Morris S.

Health Econ Rev. 2014 Dec;4(1):26. doi: 10.1186/s13561-014-0026-2. Epub 2014 Oct 23.

10.

Antitumor activity in RAS-driven tumors by blocking AKT and MEK.

Tolcher AW, Khan K, Ong M, Banerji U, Papadimitrakopoulou V, Gandara DR, Patnaik A, Baird RD, Olmos D, Garrett CR, Skolnik JM, Rubin EH, Smith PD, Huang P, Learoyd M, Shannon KA, Morosky A, Tetteh E, Jou YM, Papadopoulos KP, Moreno V, Kaiser B, Yap TA, Yan L, de Bono JS.

Clin Cancer Res. 2015 Feb 15;21(4):739-48. doi: 10.1158/1078-0432.CCR-14-1901. Epub 2014 Dec 16.

11.

Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects.

Anderson MS, Gilmartin J, Cilissen C, De Lepeleire I, Van Bortel L, Dockendorf MF, Tetteh E, Ancona JK, Liu R, Guo Y, Wagner JA, Butterton JR.

Antivir Ther. 2015;20(4):397-405. doi: 10.3851/IMP2920. Epub 2014 Dec 3.

PMID:
25470746
12.

Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers.

Yap TA, Yan L, Patnaik A, Tunariu N, Biondo A, Fearen I, Papadopoulos KP, Olmos D, Baird R, Delgado L, Tetteh E, Beckman RA, Lupinacci L, Riisnaes R, Decordova S, Heaton SP, Swales K, deSouza NM, Leach MO, Garrett MD, Sullivan DM, de Bono JS, Tolcher AW.

Clin Cancer Res. 2014 Nov 15;20(22):5672-85. doi: 10.1158/1078-0432.CCR-14-0868. Epub 2014 Sep 19.

13.

Arthroscopic Repair of Full-Thickness Rotator Cuff Tears With and Without Acromioplasty: Randomized Prospective Trial With 2-Year Follow-up.

Abrams GD, Gupta AK, Hussey KE, Tetteh ES, Karas V, Bach BR Jr, Cole BJ, Romeo AA, Verma NN.

Am J Sports Med. 2014 Jun;42(6):1296-303. doi: 10.1177/0363546514529091. Epub 2014 Apr 14.

PMID:
24733157
14.

Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.

Molife LR, Yan L, Vitfell-Rasmussen J, Zernhelt AM, Sullivan DM, Cassier PA, Chen E, Biondo A, Tetteh E, Siu LL, Patnaik A, Papadopoulos KP, de Bono JS, Tolcher AW, Minton S.

J Hematol Oncol. 2014 Jan 3;7:1. doi: 10.1186/1756-8722-7-1.

15.

A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors.

Hudis C, Swanton C, Janjigian YY, Lee R, Sutherland S, Lehman R, Chandarlapaty S, Hamilton N, Gajria D, Knowles J, Shah J, Shannon K, Tetteh E, Sullivan DM, Moreno C, Yan L, Han HS.

Breast Cancer Res. 2013 Nov 19;15(6):R110. doi: 10.1186/bcr3577.

16.

Systematic review of drug administration costs and implications for biopharmaceutical manufacturing.

Tetteh E, Morris S.

Appl Health Econ Health Policy. 2013 Oct;11(5):445-56. doi: 10.1007/s40258-013-0045-x. Review.

PMID:
23846573
17.

Basic science and surgical treatment options for articular cartilage injuries of the knee.

Tetteh ES, Bajaj S, Ghodadra NS.

J Orthop Sports Phys Ther. 2012 Mar;42(3):243-53. doi: 10.2519/jospt.2012.3673. Epub 2012 Feb 29. Review.

PMID:
22383075
18.

Managing poorly performing clinicians: health care providers' willingness to pay for independent help.

Watson V, Sussex J, Ryan M, Tetteh E.

Health Policy. 2012 Mar;104(3):260-71. doi: 10.1016/j.healthpol.2011.12.006. Epub 2012 Jan 16.

PMID:
22251755
19.

Renal insufficiency has no effect on the pharmacokinetics of vicriviroc in a ritonavir-containing regimen.

Kasserra C, Sansone-Parsons A, Keung A, Tetteh E, Assaf M, O'Mara E, Marbury T.

Clin Pharmacokinet. 2010 Jun;49(6):397-406. doi: 10.2165/11319470-000000000-00000.

PMID:
20481650
20.

Creating reliable pharmaceutical distribution networks and supply chains in African countries: Implications for access to medicines.

Tetteh E.

Res Social Adm Pharm. 2009 Sep;5(3):286-97. doi: 10.1016/j.sapharm.2008.08.001. Epub 2009 Feb 3. Review. No abstract available.

PMID:
19733829
21.

Policies and institutional arrangements for rationalizing drug selection and consumption patterns in African healthcare systems.

Tetteh EK.

Res Social Adm Pharm. 2009 Sep;5(3):274-85. doi: 10.1016/j.sapharm.2008.08.007. Epub 2009 Jan 21.

PMID:
19733828
22.

Implementing differential pricing for essential medicines via country-specific bilateral negotiated discounts.

Tetteh EK.

Appl Health Econ Health Policy. 2009;7(2):71-89. doi: 10.2165/10899640-000000000-00000.

PMID:
19731966
23.
24.

Modulation of nuclear internalization of Tat peptides by fluorescent dyes and receptor-avid peptides.

Shen D, Liang K, Ye Y, Tetteh E, Achilefu S.

FEBS Lett. 2007 May 1;581(9):1793-9. Epub 2007 Apr 4.

Supplemental Content

Loading ...
Support Center